Background and Purpose: Free radical generation mediates part of the ischemic neuronal damage caused by the excitatory amino acid glutamate. Carvedilol, a novel multiple-action antihypertensive agent, has been shown to scavenge free radicals and inhibit lipid peroxidation in swine heart and rat brain homogenates. Therefore, we studied the neuroprotective effect of carvedilol on cultured cerebellar neurons and on CA1 hippocampal neurons of gerbils exposed to brain ischemia.
W e have studied TV-methyl-D-aspartate (NMDA)
receptor-mediated excitotoxicity and have previously characterized the pharmacology of NMDA receptor-mediated neurotoxicity in cultured rat cerebellar granule cells. 1 -7 This neuronal system has become our in vitro ischemia model since we have found glutamate neurotoxicity to be markedly dependent upon the energy state of the cell. 5 Potentiation of excitatory amino acid (EAA) toxicity can be achieved by withholding glucose or oxygen or by treating the neurons with metabolic poisons to lower cellular adenosine triphosphate levels. 1 Under these in vitro ischemic conditions, cellular energy metabolism is compromised and neurons cannot maintain a membrane potential sufficient to restore the voltage-dependent Mg gated channel. 3 Recent reports of ischemia-induced neuronal damage have implicated free radical formation as an additional neurotoxic mechanism, both following and enhancing glutamate release, with antioxidants and free radical scavengers such as vitamin E, mannitol, superoxide dismutase, and catalase protecting against glutamate excitotoxicity or release. 8 "
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Carvedilol ( Figure 1 ) is a novel multiple-action antihypertensive drug (reviewed in Reference 11) that has recently been introduced to European markets. Clinical trial comparisons with other major antihypertensive agents demonstrated that once-daily therapy with carvedilol provided effective control of blood pressure with a favorable side-effect profile. 11 Carvedilol is both a competitive /3-adrenoceptor antagonist and a vasodilator, with additional calcium channel antagonist properties at somewhat higher concentrations. 12 - 14 We have recently reported that carvedilol is also a potent inhibitor of lipid peroxidation in swine ventricular membranes. 15 In that system, carvedilol was shown to have a potency similar to the 21-aminosteroid antioxidant U74500A but was far better than all other /3-blockers. 15 Carvedilol also in a dose-dependent manner inhibited superoxide release from human neutrophils, 16 scavenged superoxide radicals, 16 and inhibited lipid peroxidation in rat brain homogenates exposed to free radical-generating systems. 17 Furthermore, we have also shown the efficacy of carvedilol in promoting myocardial salvage after ischemia induced by transient or permanent ligation of the coronary artery in several species.
I4 - 18 -20 Cerebral ischemia and injury are also known to be accompanied by lipid peroxidation following oxygen free radical formation, 2 '- 23 and antioxidants such as the "lazaroids" are potent inhibitors of lipid peroxidation, 22 -24 decreasing tissue damage and increasing neuronal salvage.
22
- 25 Similarly, the free radical scavenger superoxide dismutase is currently being studied in clinical trials as a neuroprotectant in traumatic brain injury. Therefore, we hypothesized that carvedilol would afford significant protection for neurons exposed to toxic free radicals and have tested this hypothesis in our model of cultured rat cerebellar granule cells and in the gerbil model of global brain ischemia.
Materials and Methods
Primary cultures of rat cerebellar neurons were prepared from 8-day-old Sprague-Dawley rat pups (Taconic Farms, Germantown, N.Y.) and used after 7-9 days in culture. 1 -7 Cerebellar granule cell cultures grown in 35-mm dishes were deprived of glucose for 40 minutes prior to being exposed to glutamate or a free radicalgenerating system (DHF-Fe 3+ /ADP) with final concentrations of 0.83 mM dihydroxyfumarate (DHF), 0.025 mM FeCl 3 , and 0.25 mM adenosine diphosphate (ADP), which generates superoxide anions and hydroxyl radicals. 26 Carvedilol was obtained from Boehringer Mannheim, Germany, and used as the racemic mixture unless otherwise noted. It was dissolved in 100% dimethyl sulfoxide (DMSO) to 10 mM and diluted for use in 20% DMSO in assay buffer, with the final concentration of DMSO in all experiments (including vehicular controls) not exceeding 0.2%.
For analysis of lipid peroxidation, cerebellar granule cells grown in 60-mm dishes were incubated in the absence of glucose for 40 minutes before the addition of the DHF-Fe 3+ /ADP free radical-generating system. Carvedilol was incubated with the cells in a total volume of 3 ml for 15 minutes before a 20-minute exposure to DHF-Fe 3+ /ADP. Contents of the dishes were then removed and replaced with 3 ml buffer, and after 50 minutes the reaction was stopped by adding 0.3 ml of 2% butylated hydroxytoluene. 27 Assays were performed in duplicate for the indicated number of experiments.
An alternate method examined lipid peroxidation by adding FeCl 2 /vitamin C (25 /xM/100 /JLM, final concentrations 28 ) as above but with continuous incubation. The advantage of the FeCl 2 /vitamin C method was that it did not interfere with the subsequent lipid peroxidation assay and could remain in the culture dish throughout the incubation period. Furthermore, we found that FeCl 2 /vitamin C produced relatively more lipid peroxidation products (thiobarbituric acid-reactive substance [TBARS]) than did DHF-Fe 3+ /ADP in swine heart, and carvedilol was more potent against FeG 2 /vitamin C than against DHF-Fe 3+ /ADP. 15 Dish contents were scraped and removed to a glass conical tube, followed with a wash of 0.6 ml deionized water, which was also added to the tube. Samples were then assayed for the lipid peroxidation product malondialdehyde, which is split from peroxidized polyunsaturated fatty acids, by using the TBARS assay, a rapid, convenient method for estimating lipid peroxidation.
15 -17 -24 -28 TBARS was assessed by adding 1 ml thiobarbituric acid (TBA) reagent (0.335% wt/vol TBA in 50% acetic acid) to the sample and placing the tube in a boiling water bath for 30 minutes. After cooling, 4 ml n-butanol was added to extract TBARS, and the tube was centrifuged at l,000g for 20 minutes. The butanol phase was measured at 532 nm, and results were compared with a standard curve of malonaldehyde bis-dimethylacetal prepared in the same fashion.
Our use of the Mongolian gerbil model of global forebrain ischemic stroke has been previously reported. 7 In brief, male Mongolian gerbils weighing 60-70 g (Tumblebrook Farms, West Brookfield, Mass.) were anesthetized with 2.5% isoflurane in a mixture with 100% O 2 , placed onto a 37°C heating pad to keep body temperature change to <1°C during ischemia, exposed to bilateral carotid artery occlusion for 6 minutes, and allowed to recover on the heating pad for 10 minutes. For administration to the gerbils, carvedilol was dissolved in 100% DMSO, then diluted in 0.9% saline to achieve a final concentration of 3 mg/ml of 55% DMSO in saline. Therefore, the maximum amount of solution delivered in one dose did not exceed 70 /xl. Vehicletreated animals received up to 70 /xl of 55% DMSO in saline for each appropriately matched injection of carvedilol. Carvedilol was given as a subcutaneous injection, either twice (as a 1 mg/kg pretreatment 30 minutes before ischemia and as a posttreatment 4 hours after ischemia) or in a multiple dosing regimen (pretreatment with a bolus of 3 mg/kg s.c. b.i.d. for 4 days before ischemia and as posttreatment with the same dosing regimen for 3 days thereafter). Seven days after occlusion, bilateral neuronal counts over a 750-^m section of the hippocampal CA1 regions stained in 0.1% thionin were determined by microscopic examination of coded slides to ensure unbiased observations.
Data in text and figures are mean±SEM. Statistical analysis was performed as indicated in the figure legends; significant difference was accepted at p<0.05.
Results
Carvedilol potently protected cerebellar granule cells against glutamate-mediated excitotoxicity with an inhibitory concentration (IC 50 ) of 1.1 ^M (Figure 2, / to oxygen free radical scavenging, we exposed the neurons to a hydroxyl radical-generating system. After 60 minutes of exposure to DHF-Fe 3+ /ADP, cell mortality was >95% as assessed by staining with fluorescein diacetate. Untreated neurons were unaffected by the lack of glucose, as previously reported.
1 - 2 We calculated the effective time required for killing 50% of the cells (ET 50 ) to be 25.3 minutes (n-3; best-fit linear regression, R 2 =0.82). Incubating neurons with 10 ^M carvedilol for 15 minutes before the addition of DHF-Fe 3+ / ADP increased the ET 50 to 42.7 minutes (n=4; best-fit quadratic regression, R 2 =0.85). Despite the 17-minute improvement in the neuroprotective time course, protection was not total. We therefore reduced the DHFFe 3+ /ADP exposure to a 20-minute challenge, removing the DHF-Fe 3+ /ADP free radical-generating system and replacing it with glucose-free buffer. Cells exposed to a 20-minute challenge in the continual presence of glucose were resistant to free radicals for at least 24 hours. As shown in Figure 3 , cell mortality was nearly complete 50 minutes after replacement of the generating system with glucose-free buffer. Carvedilol protected against the 20-minute oxidative challenge in a dose-dependent fashion, with an IC 50 of 5 fjM (Figure 3 ) and significant protection evident at 2 pM («=8, p=0.02). Again, carvedilol extended the temporal course of neuroprotection so that neurons that received 10 /xM carvedilol during a 20-minute challenge with DHF-Fe 3+ /ADP succumbed only 24 ±8 minutes («=4) before unchallenged control cells in glucose-free buffer, which maintained viability for up to 3 hours. If glucose-containing buffer were added after the "ischemic" oxidative challenge, then carvedilol was able to provide total neuronal protection for up to 8 hours. Challenged neurons provided with glucose but not carvedilol were only 0-20% viable after 6-8 hours. When the separate (+) and ( -) enantiomers of carvedilol were tested in this model, no differences in neuroprotective ability were seen. These results strengthened our previous findings in heart and brain homogenates 1517 that protection by carvedilol from lipid peroxidation was not ( -) enantiomer-selective, as would be expected for a /3-adrenoceptor antagonist, and was not a function of /3-blockade. However, some /3-adrenoceptor antagonists such as propranolol have been shown to prevent lipid peroxidation (IC 50 =103 /iM). 26 Because carbazole derivatives such as carvedilol are lipid-soluble, 29 we examined the effect of prolonged pretreatment by growing neurons in the presence of carvedilol for 24 hours. Even after removal of the treated growth medium and several buffer washes, treated cells were still significantly resistant to a 20-minute oxidative challenge with free radicals. However, a greater effect was observed by augmenting the 24 hour-treated cells with the additional 15-minute pretreatment presented in Figure 3 . The effect of the augmented treatment was to enhance neuroprotection by shifting the IC 50 from 5 juM to 1.3 /AM (Figure 4) . Although DMSO can be a free radical scavenger, 30 we never saw a protective effect of up to 1% DMSO in any of our toxicity assays.
Using the same experimental procedure, we studied the ability of carvedilol to prevent lipid peroxidation induced by the DHF-Fe 3+ /ADP free radical-generating system. Lipid peroxidation of neurons grown in 60-mm dishes was assessed by measuring the amount of TBARS produced 50 minutes after washout of the generating system; the DHF-Fe 3+ /ADP had to be removed because of interference with the TBARS assay. We found that a 15-minute pretreatment with 10 /xM carvedilol provided a 50% reduction (n=4,/><0.001) of the amount of TBARS produced by a 20-minute challenge of DHF-Fe 3+ /ADP ( Figure 5 ), consistent with carvedilol's free radical-scavenging mechanism that we have observed in heart and brain homogenates 15 . 17 and with human neutrophils. 16 Carvedilol was even more potent against continuous exposure to an alternate free radical-generating system composed of Fe 2+ /vitamin C. As shown in Figure 6 , pretreatment with 10 yM carvedilol for 15 minutes before the addition of Fe 2+ /vitamin C provided a 73% reduction in TBARS production (n=4,/?<0.001). Again, up to 1% DMSO alone did not inhibit TBARS production in any assay.
Carvedilol was also neuroprotective in vivo, where CA1 hippocampal neurons in gerbils exposed to 6 minutes of bilateral carotid artery occlusion were significantly protected with a multiple dosing regimen when examined 7 days after the ischemic insult (n=22, p=0.009; Figure 7 ). The multiple dosing regimen was necessary for neuroprotection because a 1 mg/kg dose administered twice as a 30-minute pretreatment followed by a 4-hour posttreatment was not neuroprotective (29±15 neurons versus 18±9 neurons for vehicletreated animals, n = 10 for each). The 3 mg/kg dose was also necessary because 1 mg/kg s.c. b.i.d. delivered as 5 days' pretreatment and 7 days' posttreatment was also not significantly neuroprotective (79±15 neurons [« = 12] versus 57±18 neurons [«=9] for vehicle-treated animals).
Discussion
Carvedilol is a unique antihypertensive compound because it is not only a vasodilator and )3-adrenergic receptor blocker but also appears to be a useful antioxidant, rapidly preventing lipid peroxidation in swine ventricular membranes 15 and rat brain homogenates 17 with a potency two orders of magnitude greater than that of other /3-blockers. 15 ' 17 ' 26 Furthermore, it appears to be an oxygen free radical scavenger, scavenging both chemically generated and human neutrophil-generated superoxide anions. 16 Compared with the lazaroid antioxidant U74500A, carvedilol is nearly equipotent against lipid peroxidation 15 and is far superior as a free radical scavenger. 1617 The antioxidant activity of carvedilol resides in the carbazole moiety. 17 Oxidative Challenge mediated protection of cerebellar granule cell neurons from glutamate excitotoxicity supports previous arguments of a role for free radical generation in ischemiainduced neuronal damage, in which free radicals generated by EAA receptor agonists would cause further EAA release. 10 Because ischemic conditions caused a 20-fold increase in glutamate release from hippocampal slices 10 cerebellar granule cells, 1 -7 continual free radical generation and neurotransmitter release would likely contribute to sustained damage during ischemic stroke. By scavenging free radicals, carvedilol would be likely to decrease EAA release; by preventing glutamate-induced toxicity as shown here, fewer free radicals would be generated.
Because carvedilol prevented neuronal death and inhibited membrane lipid peroxidation in cerebellar granule cells exposed to a free radical-generating system, the drug may be sequestered in biological membranes. Maximal plasma concentrations of carvedilol in humans averaged 173 /xg/1 (425 nM) after intravenous infusion of 12.5 mg and 66 jug/1 (162 nM) 1.2 hours after 50 mg p.o., 31 about an order of magnitude lower than the IC 5O s reported here for neuroprotection. However, carvedilol is a highly lipophilic compound 29 - 31 that is extensively bound to tissues, achieving a high distribution volume of 132 I. 31 In addition, hydroxylated derivatives of carvedilol increased the antioxidant activity 10-to 40-fold 17 and have been found as metabolites in humans. Further supportive evidence for protective membrane sequestration comes from the ability of neurons grown with carvedilol for 24 hours to better withstand free radical-mediated cell death. Indeed, the multiple-dosing regimen that we used for the gerbil neuroprotection studies favored an accumulative mechanism achieved by daily dosing because bolus injections of 1 mg/kg s.c. as a 30-minute pretreatment and 4-hour posttreatment had no protective effect. These results are similar to those reported for the nonsteroidal lazaroid U78517F in the gerbil model of 15-minute bilateral carotid artery occlusion, in that multiple dosing was required for efficacy. 25 Although cerebral protection by the lazaroids has been noted in many cases, 2225 not all investigators have found these compounds to be neuroprotective, even with repeated dosings. 32 -34 The neuroprotection results reported here support the efficacy of carvedilol as an effective free radical scavenger and inhibitor of lipid peroxidation. We suggest that carvedilol may not only relieve hypertension as a risk factor for stroke, but will also be better able to provide additional benefits to patients by protecting against oxygen free radicals generated during cerebral ischemia and stroke.
Editorial Comment
In an attempt to develop a protective stroke therapy, investigators have sought specific molecular mechanisms causally related to the development of neuronal death that occurs after ischemic insults. During the past year, Stroke has published almost a dozen articles suggesting that free radical generation in ischemic brain constitutes a pathogenic molecular event leading to infarction. In this issue, scientists from SmithKline Beecham present evidence that carvedilol, a new /3-blocker and free radical scavenger, is neuroprotective in stroke models.
